Holen Sie sich die Stockscreener-App
122.87
0.71%
0.87
Handel nachbörslich:
127.49
4.62
+3.76%
Schlusskurs vom Vortag:
$122.00
Offen:
$121.16
24-Stunden-Volumen:
4.36M
Relative Volume:
1.18
Marktkapitalisierung:
$25.97B
Einnahmen:
$381.03M
Nettoeinkommen (Verlust:
$-1.01B
KGV:
-20.65
EPS:
-5.95
Netto-Cashflow:
$-789.25M
1W Leistung:
+10.44%
1M Leistung:
+25.15%
6M Leistung:
+56.18%
1J Leistung:
+60.87%
1-Tages-Spanne:
$119.80
$123.42
1-Wochen-Bereich:
$106.54
$123.42
52-Wochen-Spanne:
$60.40
$123.42
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
122.87 | 25.79B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed and VytlOne: A Groundbreaking Partnership in Rare Disease Innovation - AInvest
VytlOne Announces New Partnership with Insmed - Yahoo Finance
Insmed stock downgraded at Morgan Stanley (INSM:NASDAQ) - Seeking Alpha
Insmed stock price target raised to $154 from $135 at TD Cowen on Brinsupri approval - Investing.com Canada
Insmed stock price target raised to $138 from $120 at RBC Capital - Investing.com Canada
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week - Stocktwits
UBS Adjusts Insmed Price Target to $140 From $133, Maintains Buy Rating - MarketScreener
PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - Yahoo Finance
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - MSN
Insmed wins FDA approval for future blockbuster Brinsupri - Yahoo Finance
Mizuho raises Insmed stock price target to $165 following Brinsupri approval - Investing.com Canada
Morgan Stanley Downgrades Insmed to Equal Weight From Overweight, Adjusts Price Target to $126 From $112 - MarketScreener
Mizuho Adjusts Price Target on Insmed to $165 From $130, Maintains Outperform Rating - MarketScreener
Mizuho Raises Price Target for Insmed (INSM) to $165 | INSM Stoc - GuruFocus
Insmed secures FDA approval for Brinsupri to treat NCFB - World Pharmaceutical Frontiers
Insmed stock price target raised to $140 at UBS on Brinsupri approval - Investing.com Canada
Jefferies Raises Price Target on Insmed (INSM) to $148 | INSM St - GuruFocus
Insmed gets first FDA approval for bronchiectasis - pharmaphorum
Insmed stock rating downgraded to Equalweight by Morgan Stanley - Investing.com Canada
Insmed (INSM) Receives Positive Analyst Ratings and Price Target Increases - AInvest
Insmed (INSM) Surges 8.07% as Bullish Candlesticks and MACD Golden Cross Signal 65% Outperformance Probability - AInvest
Insmed Surges 8.07% on FDA Approval as $870M Trading Volume Hits Top 500 Daily Rank - AInvest
US FDA approves Insmed's drug as first treatment for a chronic lung disease - Reuters
Wells Fargo Raises Price Target for INSM to $140, Maintains Over - GuruFocus
Insmed: Wells Fargo Reiterates Overweight, Raises PT to $140 from $130 - AInvest
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - AOL.com
FDA Approves Insmed’s Brensocatib as First Therapy for Non-Cystic Fibrosis Bronchiectasis - geneonline.com
Insmed gains US approval of lung disease drug forecast to be blockbuster - BioPharma Dive
Brinsupri dose choice means bronchiectasis upside, Insmed says - BioWorld MedTech
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval - Investor's Business Daily
Jefferies raises Insmed stock price target to $148 on Brinsupri approval - Investing.com Canada
Insmed scores FDA clearance for Brinsupri in NCFB - BioWorld MedTech
FDA Approves Insmed's Brinsupri for Chronic Lung Disease Treatment - AInvest
Why Is Insmed Stock Trading Higher TodayInsmed (NASDAQ:INSM) - Benzinga
US FDA approves Insmed’s drug as first treatment for a chronic lung disease - The Mighty 790 KFGO
Insmed gets FDA approval for the first DPP1 inhibitor, in lung disease - Endpoints News
Insmed's Brinsupri: A Blockbuster Launch in a Neglected Market - AInvest
Insmed stock rises on FDA nod for lung disorder drug Brinsupri - Seeking Alpha
Insmed stock surges after FDA approves first NCFB treatment By Investing.com - Investing.com Canada
Insmed's FDA Approval of Brinsupri: A Strategic Win in the Orphan Drug Market and Its Implications for Shareholder Value - AInvest
US FDA approves Insmed's lung disease drug - Reuters
Insmed Drug Wins First US Approval for Debilitating Lung Disease - Bloomberg.com
FDA Makes History: First-Ever Treatment for 500,000 Non-Cystic Fibrosis Bronchiectasis Patients Gets Approval - Stock Titan
Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest
Insmed's 3.28% Two-Day Rally Fueled by Strong Candlestick Momentum and Bullish Moving Averages - AInvest
Insmed Surges 3.05% on 28.6% Japan Revenue Spike as $370M Volume Ranks 271st in Market Activity - AInvest
Insmed Hovers Near 110 Resistance As Technicals Signal Consolidation Risk - AInvest
Insmed stock hits 52-week high at 113.17 USD By Investing.com - Investing.com Nigeria
Insmed stock hits 52-week high at 113.17 USD - Investing.com
Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock - Yahoo Finance
Liquidia: Uncertainty Has Always Been A Buying Opportunity (LQDA) - Seeking Alpha
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):